Chiron Real Estate

XRN · NYSE

$29.98+$0.49 (+1.66%)TodayMarket closed · Oct 20, 7:35 PM ET

Prev close $29.49

XRN analyst rating

HoldConsensus of 5 analysts over the last 12 months. 40% rate it a buy.

Strong buy0
Buy2
Hold3
Underperform0
Sell0

12-month price target · 10 analysts

Average $42.50 (+41.8% upside)

Low: $37.37
Now: $29.98
High: $48.30

Upgrades and downgrades

The latest rating actions, newest first

XRN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Cantor Fitzgerald	Sep 21, 2026	Initiates	Overweight	$43.00	55%
BMO Capital	Jul 13, 2026	Maintains	Market Perform	$39.00 → $40.00	56%
Raymond James	Jun 17, 2026	Initiates	Market Perform	—	53%
Citizens	May 26, 2026	Maintains	Market Outperform	$40.00 → $42.00	40%
BMO Capital	May 18, 2026	Maintains	Market Perform	$33.00 → $39.00	56%
Compass Point	May 7, 2026	Downgrade	Buy → Neutral	$50.00 → $38.00	48%

The case for and against

Updated Oct 21, 2026

Bull case

Chiron Real Estate is attractive because it is executing a deliberate pivot from legacy medical office assets into higher-growth SHOP and active adult housing, supported by trophy-quality acquisitions in supply-constrained markets and a repeatable development-to-acquisition pipeline. The balance sheet transition looks manageable, with $266mm of dispositions funding $249mm of SHOP acquisitions, net debt to adjusted EBITDAre improving to 6.0x, $642mm of total debt, 78% fixed-rate exposure, a 4.6% weighted average interest rate, and no debt maturities until 2028. Although FAD per share is expected to trough in 2026-2027 as lease-up creates near-term dilution, management’s hiring of specialized senior housing talent, same-store cash NOI growth of 3.2%, and implied 7%+ stabilized yields suggest a credible path to stronger earnings and a re-rating as execution risk declines.

Bear case

Chiron Real Estate is facing a negative setup because its 2026 and 2027 FFO estimates of $3.10 and $2.57 imply a -17.1% y/y decline next year and another drop as lease-up costs, interest expense, preferred dividends, and G&A run ahead of NOI from assets still stabilizing. The company also cut its dividend 36% to $0.16 per month, withdrew 2026 guidance, and trades at 14.8x 2027E AFFO despite being the only peer expected to post a 2027E AFFO decline, underscoring near-term earnings pressure. On top of that, its concentration in a limited set of states and reliance on healthcare tenants exposes it to reimbursement, regulatory, economic, and tenant credit risk, while even a modest slowdown in rent growth or a large tenant default could pressure cash flow and sentiment.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.